AC
AI Cancer Cure

Evidence Atlas, updating nightly

Explore

Cancer trials

Pediatric cancers (general) trials

Recruiting and active trials mapped to Pediatric cancers (general). Adjust filters as needed.

17 trialsSorted by top rated
RECRUITINGRating 87

Phase

Not listed

Sponsor

University of Geneva, Switzerland

Last update

2026-01-15

Patient usefulness rating

87/100

Relevance score

47/100

Conditions

ALL, Childhood, Pediatric Cancer, Toxicity, Drug, Adverse Drug Event +4

Interventions

Not listed

Eligibility

Inclusion Criteria: * Age \> 1 year old and ≤18 years old at enrolment * Previously untreated * ALL diagnosis confirmed by morphology and flow-cytometry * Indian origins * Fulfilling IciCle treatment…

Locations

2 sites

AI-generated summary

Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia is being studied. Conditions: ALL, Childhood, Pediatric Cancer, Toxicity, Drug +5 • Eligibility: Inclusion Criteria: * Age \> 1 year old and ≤18 years old at enrolment * Previously untreated * ALL diagnosis confirmed by morphology and flow-cytometry * Indian origins…. Goal: A five-year prospective observational cohort study. The study is focused on observing the relation between static germline variants and therapeutic response in Indian children with acute lymphoblastic leukemia (ALL). Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Geneva, Switzerland.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

Primary source facts: ClinicalTrials.gov metadata.

RECRUITINGRating 85

Phase

Not listed

Sponsor

University of Edinburgh

Last update

2025-11-20

Patient usefulness rating

85/100

Relevance score

46/100

Conditions

Fertility Disorders, Childhood Cancer

Interventions

Not listed

Eligibility

Inclusion Criteria: * Pre- and peripubertal boys * Due to receive cancer treatment that is predicted to have a high risk (\>80%) of infertility * Consent to removal of testicular tissue for…

Locations

1 sites

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

Primary source facts: ClinicalTrials.gov metadata.

NOT_YET_RECRUITINGRating 83

Phase

Not listed

Sponsor

Rigshospitalet, Denmark

Last update

2026-01-30

Patient usefulness rating

83/100

Relevance score

45/100

Conditions

Pediatric Cancer, Pediatric Cancer Patients

Interventions

Not listed

Eligibility

Inclusion Criteria: * Children newly diagnosed with cancer or cancer-like benign disorders. * Children between the ages of ≥12 to \<72 months at the time of treatment initiation. * Children undergoing chemotherapy…

Locations

1 sites

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

Primary source facts: ClinicalTrials.gov metadata.

RECRUITINGRating 82

Phase

Not listed

Sponsor

University Hospital, Angers

Last update

2025-07-02

Patient usefulness rating

82/100

Relevance score

45/100

Conditions

Pediatric Cancer, Cancer Survivor, Hemato-oncologic Patients

Interventions

Not listed

Eligibility

Inclusion Criteria: * Previously treated for cancer or malignant hematological pathology before the age of 25 * Without residual disease or with a stable disease without treatment for 5 years or more…

Locations

1 sites

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

Primary source facts: ClinicalTrials.gov metadata.

RECRUITINGRating 81

Phase

Not listed

Sponsor

Rigshospitalet, Denmark

Last update

2020-10-09

Patient usefulness rating

81/100

Relevance score

44/100

Conditions

Pediatric Cancer

Interventions

Not listed

Eligibility

Inclusion Criteria: * Age 5-17 years. * Patients with a tumor in the mediastinum or abdomen with possible need of radiotherapy according to current treatment guidelines, irrespective of cancer diagnosis. * The…

Locations

3 sites

AI-generated summary

Radiotherapy Delivery in Deep Inspiration for Pediatric Patients is being studied. Conditions: Pediatric Cancer • Eligibility: Inclusion Criteria: * Age 5-17 years. * Patients with a tumor in the mediastinum or abdomen with possible need of radiotherapy according to current treatment guidelines, irrespective of…. Goal: TEDDI is a non-randomised phase II trial in Scandinavia. All pediatric patients, referred for radiotherapy in the thorax or abdomen and irrespective of diagnosis, are eligible. Phase/Status/Sponsor: Unknown phase; RECRUITING; Rigshospitalet, Denmark.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

Primary source facts: ClinicalTrials.gov metadata.

NOT_YET_RECRUITINGRating 79

Phase

Not listed

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Last update

2026-02-02

Patient usefulness rating

79/100

Relevance score

44/100

Conditions

Adolescent Cancer Survivors, Childhood Cancer Survivors, Anxiety

Interventions

Not listed

Eligibility

Inclusion Criteria: HARMONY KIDS * Patients aged at least 7 and under 15 at the time of inclusion, diagnosed with pediatric cancer, * Patients considered to be in complete remission from pediatric…

Locations

7 sites

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

Primary source facts: ClinicalTrials.gov metadata.

RECRUITINGRating 79

Phase

Not listed

Sponsor

Centre Hospitalier Universitaire de Liege

Last update

2024-11-01

Patient usefulness rating

79/100

Relevance score

44/100

Conditions

Childhood Cancer Survivors, Fertility, Ovarian Reserve, CED +4

Interventions

Not listed

Eligibility

Inclusion Criteria: * Child and adolescent female patients included in the Paediatrics Late Effects Project: * diagnosed with cancer1 between 01/01/2004 and 31/12/2018 * \<17 years old at diagnosis * treated at…

Locations

3 sites

AI-generated summary

Fertility and Ovarian Reserve in Female Childhood Cancer Survivors is being studied. Conditions: Childhood Cancer Survivors, Fertility, Ovarian Reserve +5 • Eligibility: Inclusion Criteria: * Child and adolescent female patients included in the Paediatrics Late Effects Project: * diagnosed with cancer1 between 01/01/2004 and 31/12/2018 * \<17 years old at…. Goal: Ovarian function impairment affects the quality of life of the survivors of paediatric cancer by impacting fertility, bone quality and mental and cognitive health. The objective of this project is to evaluate the impact of low-intermediate dose alkylating agents associated or not with ovarian cryopreservation technique on ovarian function in female survivors of paediatric cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Centre Hospitalier Universitaire de Liege.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

Primary source facts: ClinicalTrials.gov metadata.

ACTIVE_NOT_RECRUITINGRating 73

Phase

Not listed

Sponsor

Children's Oncology Group

Last update

2026-01-09

Patient usefulness rating

73/100

Relevance score

41/100

Conditions

Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm

Interventions

Not listed

Eligibility

Inclusion Criteria: * First diagnosis of malignant neoplasm (International Classification of Diseases for Oncology \[ICD-O\] behavior code of "3") in first and continuous remission at the time of enrollment * Curative cancer…

Locations

116 sites

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

Primary source facts: ClinicalTrials.gov metadata.

NOT_YET_RECRUITINGRating 70

Phase

Not listed

Sponsor

Universidad de Granada

Last update

2025-07-15

Patient usefulness rating

70/100

Relevance score

40/100

Conditions

Cancer Survivors

Interventions

Not listed

Eligibility

Inclusion Criteria: * Prior diagnosis of pediatric cancer and history of receiving treatment (radiation therapy and/or chemotherapy). * 18-55 years of age at recruitment Exclusion Criteria: * Participation in another research study…

Locations

1 sites

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

Primary source facts: ClinicalTrials.gov metadata.

ACTIVE_NOT_RECRUITINGRating 69

Phase

Not listed

Sponsor

AstraZeneca

Last update

2024-10-29

Patient usefulness rating

69/100

Relevance score

40/100

Conditions

Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies

Interventions

Not listed

Eligibility

Inclusion Criteria: * Max Age =17 years * Solid Tumors (except primary central nervous system malignant tumors): Patients must have a histopathologic confirmation of malignancy. Patients must have progressed or are refractory…

Locations

19 sites

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

Primary source facts: ClinicalTrials.gov metadata.

NOT_YET_RECRUITINGRating 67

Phase

Not listed

Sponsor

Nere Mendizabal

Last update

2024-08-20

Patient usefulness rating

67/100

Relevance score

39/100

Conditions

Exercise, Childhood Cancer

Interventions

Not listed

Eligibility

Inclusion Criteria: * Patients diagnosed with cancer and other neoplasms * Age between 4 and 18 years at the time of inclusion in the study * Patients diagnosed with cancer and other…

Locations

Not listed

AI-generated summary

The study tests whether a supervised, personalized physical exercise program is feasible and can improve functional capacity and quality of life for children and adolescents with cancer. It enrolls people aged 4 to 18 with any type of cancer, including those currently receiving treatment or with relapse. The trial aims to learn about feasibility, recruitment and adherence, and to measure changes before and after the exercise program to identify reliable outcome measures for future trials. Key exclusions include cognitive deficits, severe neurological conditions that prevent exercise, language barriers, and very low functional status (Lansky <60% for under 16, Karnofsky <60% for 16 and older). The study is not yet recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

Primary source facts: ClinicalTrials.gov metadata.

ENROLLING_BY_INVITATIONRating 64

Phase

Not listed

Sponsor

Universitair Ziekenhuis Brussel

Last update

2025-04-01

Patient usefulness rating

64/100

Relevance score

38/100

Conditions

Childhood Cancer, Hematological Disorders

Interventions

Not listed

Eligibility

Inclusion criteria * young adult men (≥18 years) * diagnosis of cancer or hematological disorder during childhood (\<18 years) * high-risk gonadotoxic treatment received during childhood * at least one year after…

Locations

1 sites

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

Primary source facts: ClinicalTrials.gov metadata.

UNKNOWNRating 59

Phase

Not listed

Sponsor

Sun Yat-sen University

Last update

2022-05-09

Patient usefulness rating

59/100

Relevance score

36/100

Conditions

Rituximab, Lymphoma, Non-Hodgkin, Pediatric Cancer

Interventions

Not listed

Eligibility

Inclusion Criteria: 1. Age \< 18 years old 2. Pathologically confirmed Burkitt lymphoma or diffuse large B-cell lymphoma 3. Newly diagnosed patients 4. Informed consent of guardian of children patients Exclusion Criteria:…

Locations

1 sites

AI-generated summary

Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCL is being studied. Conditions: Rituximab, Lymphoma, Non-Hodgkin, Pediatric Cancer • Eligibility: Inclusion Criteria: 1. Age \< 18 years old 2. Pathologically confirmed Burkitt lymphoma or diffuse large B-cell lymphoma 3. Newly diagnosed patients 4. Informed consent of guardian of…. Goal: The trial SCCCG-BL/DLBCL-2017 is a collaborative prospective, multicenters, non-randomized, observational, cohort clinical study with participating centers of the South China Children's Cancer Group-Non-Hodgkin lymphoma group(SCCCG-NHL). The aim of the study is to evaluate efficacy and safety of stratified treatment based on risk factors of childhood and adolescents Burkitt lymphoma(BL)/diffuse large B-cell lymphoma(DLBCL) patients in china. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

Primary source facts: ClinicalTrials.gov metadata.

COMPLETEDRating 54

Phase

Not listed

Sponsor

Gazi University

Last update

2025-09-29

Patient usefulness rating

54/100

Relevance score

34/100

Conditions

Childhood Cancer, ALL, Childhood, AML, Childhood, Lymphoma +1

Interventions

Not listed

Eligibility

Implementation and Evaluation of the School Re-entry Adaptation Program Inclusion Criteria For Children: Aged between 8 and 17 years Diagnosed with cancer (leukemia, lymphoma, or solid tumor) For children diagnosed with leukemia,…

Locations

1 sites

AI-generated summary

Retun-to-school Adaptation Program for Children With Cancer is being studied. Conditions: Childhood Cancer, ALL, Childhood, AML, Childhood +2 • Eligibility: Implementation and Evaluation of the School Re-entry Adaptation Program Inclusion Criteria For Children: Aged between 8 and 17 years Diagnosed with cancer (leukemia, lymphoma, or solid tumor) For…. Goal: The aim of this action research is to: Stage 1: Conduct an in-depth investigation into the adaptation challenges faced by children aged 8-17 who are being treated for cancer during their return to school, from both the children's and parents' perspectives; Stage 2: Develop a structured, evidence-based, and digitally accessible intervention program that addresses these identified needs; Stage 3: Evaluate the feasibility and effectiveness of the intervention; and Ultimately, based on all data gathered throughout the implementation process, continuously refine the intervention and analyze participant feedback holistically in order to establish a sustainable support model. Phase/Status/Sponsor: Unknown phase; COMPLETED; Gazi University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

Primary source facts: ClinicalTrials.gov metadata.

COMPLETEDRating 51

Phase

Not listed

Sponsor

National Cancer Institute (NCI)

Last update

2024-03-04

Patient usefulness rating

51/100

Relevance score

32/100

Conditions

Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer +7

Interventions

Not listed

Eligibility

PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically documented metastatic cancer of one of the following types: Cutaneous melanoma Ocular melanoma Colorectal carcinoma Non-small cell lung cancer Breast carcinoma Sarcoma HLA-Cw\*0702 positive MAGE-12 expression…

Locations

1 sites

AI-generated summary

Vaccine Therapy in Treating Patients With Metastatic Cancer is being studied. Conditions: Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer +8 • Eligibility: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically documented metastatic cancer of one of the following types: Cutaneous melanoma Ocular melanoma Colorectal carcinoma Non-small cell lung cancer Breast carcinoma Sarcoma…. Goal: RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic cancer that has not responded to previous therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

Primary source facts: ClinicalTrials.gov metadata.

COMPLETEDRating 51

Phase

Not listed

Sponsor

University of Miami

Last update

2012-03-08

Patient usefulness rating

51/100

Relevance score

32/100

Conditions

Acute Lymphoblastic Leukemia, Central Nervous System Tumors, Lymphoma

Interventions

Not listed

Eligibility

Inclusion Criteria: * Children, ages 6-12 years, who are within 2-5 years of diagnosis for either central nervous system tumor or acute lymphocytic leukemia, or lymphoma at time of enrollment Exclusion Criteria:…

Locations

1 sites

AI-generated summary

Assessing the Effectiveness of Individual Education Plans for Childhood Cancer Survivors is being studied. Conditions: Acute Lymphoblastic Leukemia, Central Nervous System Tumors, Lymphoma • Eligibility: Inclusion Criteria: * Children, ages 6-12 years, who are within 2-5 years of diagnosis for either central nervous system tumor or acute lymphocytic leukemia, or lymphoma at time…. Goal: Neurodevelopmental outcomes in children treated for cancer involving the central nervous system (CNS) provide educators with new challenges with regards to classification, monitoring, and intervention in the regular or special education classroom setting. Recommendations resulting from serial neurodevelopmental evaluations for these children often do not overlap with traditional special education recommendations commonly included in Individual Education Plans (IEPs) for children with congenital or genetic learning problems. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Miami.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

Primary source facts: ClinicalTrials.gov metadata.

TERMINATEDRating 46

Phase

Not listed

Sponsor

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Last update

2018-12-03

Patient usefulness rating

46/100

Relevance score

30/100

Conditions

Hypopituitarism, Hypogonadism, Thyroid Dysfunction, Bone Diseases, Metabolic

Interventions

Not listed

Eligibility

* INCLUSION * Age \>2 years. * History of diagnosis of malignancy or HSCT and completion of therapy prior to entering the study. Eligible patients must be free of their underlying malignancy…

Locations

1 sites

AI-generated summary

Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoietic Stem Cell Transplant Recipients is being studied. Conditions: Hypopituitarism, Hypogonadism, Thyroid Dysfunction +1 • Eligibility: * INCLUSION * Age \>2 years. * History of diagnosis of malignancy or HSCT and completion of therapy prior to entering the study. Eligible patients must be free…. Goal: This study will determine the prevalence of endocrine-related side effects in children who have been treated for cancer and establish a database and registry organized according to cancer diagnosis, treatments and endocrine side effects. In children, the endocrine system, which includes glands and hormones that help to control metabolism, growth, development and reproduction, is particularly vulnerable to long-term side effects associated with cancer and its treatments. Phase/Status/Sponsor: Unknown phase; TERMINATED; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

Primary source facts: ClinicalTrials.gov metadata.